Corrigendum.
In the Foreword by Sandro Barni, titled "Eribulin in 'field practice': an overview of the Italian experience", which appeared in the August 2015 issue of Future Oncology 11(15s), 1–2 (2015), the following sentence was incorrectly presented as: "Casanova et al. [7] in their manuscript comment on the management of a triple-negative patient who maintained eribulin treatment for a total of nine cycles." The correct sentence is: "Casanova et al. [7] in their manuscript comment on the management of a HER2+ patient who maintained eribulin treatment for a total of nine cycles." The authors and editors would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.